Elevated Lipoprotein(a) (Lp(a)) is increasingly recognized as an important inherited genetic risk factor for atherosclerotic cardiovascular disease (ASCVD) impacting potentially > 1 billion of the global population. With the promise of new therapeutics that might markedly modify this risk, the time has arrived to move it into the spotlight, increase awareness, testing, and knowledge on what to do about it, both now and in the near future. Join Kausik Ray, Professor of Public Health, Honorary Consultant Cardiologist, Head of Commercial Trials and Deputy Director of the Imperial Clinical Trials Unit at Imperial College London and President of the European Atherosclerosis Society, and Curtis Rambaran, MD, Vice President Clinical Sciences, Silence Therapeutics, for a roundtable discussion exploring the history of Lp(a), the unmet need, importance of testing and the current state of drug development.
Professor Ray is currently President of the European Atherosclerosis Society, Chair of the World Heart Federation Cholesterol Roadmap, Chair for Global Council for Heart Health, National Lead for CVD NIHR Academic research Collaboration, Clinical Director for Research HDR UK Digital Innovation Hub DISCOVER Now and Director of ICTU-Global which is an academic ARO.
He received his medical education (MB ChB, 1991) at the University of Birmingham Medical School, his MD (2004) at the University of Sheffield, a postdoctoral fellowship at Harvard Medical School and finally an MPhil in epidemiology (2007) from the University of Cambridge. His research involves lipids, diabetes and population health serving as global lead for trials and registries. He has >150,000 citations and since 2018 has been recognised by Clarivate Analytics as among the top 0.1% of authors in global medicine. In 2023 he was inducted as a Fellow of the Academy of Medical Sciences, which is UK’s highest honour for clinician scientists.
Curtis Rambaran joined Silence Therapeutics as VP and Head of the Clinical Science group in January 2021. He received his medical degree from the University of the West Indies, followed by residency training in Yorkshire, UK, then completed a Wellcome Trust Cardiology Research Fellowship at King’s College London, with subsequent specialty training in Cardiovascular Medicine and Clinical Pharmacology at Guy’s & St Thomas’ Hospital London. Curtis joined the Respiratory Translational Medicine team at GlaxoSmithKline (GSK) in 2009 developing first in human and experimental medicine studies for novel oral and inhaled assets. He then moved on to the Cardiovascular Therapy Area to work on several outcome studies (CVOTs) with novel MOA including Darapladib and Losmapimod. Following this, he became European Head of Translational Medicine and Clinical Pharmacology at Daiichi Sankyo UK crossing the pond a year later to work with the US NJ team where he led early development and later-stage clinical programs across cardio-renal and rare diseases. Highlights include development of potent anti-inflammatory therapies in coronary artery disease and COPD, human induced pluripotent stem cells for heart failure, NaPi-IIb Inhibition for hyperphosphatemia in chronic kidney disease and an RNA antisense oligonucleotide for Duchenne Muscular Dystrophy.
Surani Fernando is a seasoned healthcare journalist and editor with over 13 years experience covering the biopharma industry. A Sydney native, she started her investigative journalism career in London covering clinical trials, M&A and financing deals for BioPharm Insight, later moving to New York to continue her work as an enterprise journalist and editorial leader for GlobalData and Reorg. She is now based in Madrid working as a freelance journalist, consultant writer and podcast producer.